| [1] |
Berezin A.Metabolic memory phenomenon in diabetes mellitus:achieving and perspectives[J].Diabetes Metab Syndr,2016,10(2 Suppl 1):S176-S183.
|
| [2] |
de Oliveira AA,de Oliveira TF,Bobadilla LL,et al.Sustained kidney biochemical derangement in treated experimental diabetes:a clue to metabolic memory[J].Sci Rep,2017,7:40544.
|
| [3] |
Maghbooli Z,Hossein-nezhad A,Larijani B,et al.Global DNA methylation as a possible biomarker for diabetic retinopathy[J].Diabetes Metab Res Rev,2015,31(2):183-189.
|
| [4] |
Motiejūnaite R,Kazlauskas A.Pericytes and ocular diseases[J].Exp Eye Res,2008,86(2):171-177.
|
| [5] |
Cho SJ,Roman G,Yeboah F,et al.The road to advanced glycation end products:a mechanistic perspective[J].Curr Med Chem,2007,14(15):1653-1671.
|
| [6] |
Pop-Busui R,Martin C.Neuropathy in the DCCT/EDIC-what was done then and what we would do better now[J].Int Rev Neurobiol,2016,127:9-25.
|
| [7] |
Javed S,Alam U,Malik RA.Burning through the pain:treatments for diabetic neuropathy[J].Diabetes Obes Metab,2015,17(12):1115-1125.
|
| [8] |
Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies:update on definitions,diagnostic criteria,estimation of severity,and treatments[J].Diabetes Care,2010,33(10):2285-2293.
|
| [9] |
Bahniwal M,Little JP,Klegeris A.High glucose enhances neurotoxicity and inflammatory cytokine secretion by stimulated human astrocytes[J].Curr Alzheimer Res,2017,14(7):731-741.
|
| [10] |
Chilelli NC,Burlina S,Lapolla A.AGEs,rather than hyperglycemia,are responsible for microvascular complications in diabetes:a “glycoxidation-centric” point of view[J].Nutr Metab Cardiovasc Dis,2013,23(10):913-919.
|
| [11] |
Piperi C,Goumenos A,Adamopoulos C,et al.AGE/RAGE signalling regulation by miRNAs:associations with diabetic complications and therapeutic potential[J].Int J Biochem Cell Biol,2015,60:197-201.
|
| [12] |
Yamagishi S,Matsui T,Fukami K.Role of receptor for advanced glycation end products(RAGE)and its ligands in cancer risk[J].Rejuvenation Res,2015,18(1):48-56.
|
| [13] |
Koulis C,Watson AM,Gray SP,et al.Linking RAGE and Nox in diabetic micro- and macrovascular complications[J].Diabetes Metab,2015,41(4):272-281.
|
| [14] |
Yamagishi S,Matsui T.Role of receptor for advanced glycation end products(RAGE)in liver disease[J].Eur J Med Res,2015,20:15.
|
| [15] |
Yamagishi S I,Fukami K,Matsui T.Crosstalk between advanced glycation end products(AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications[J].Cardiovasc Diabetol,2015,14(1):2.
|
| [16] |
Manigrasso MB, Juranek J, Ramasamy R, et al. Unlocking the biology of RAGE in diabetic microvascular complications[J].Trends Endocrinol Metab,2014,25(1):15-22.
|
| [17] |
Yamagishi SI,Nakamura N,Matsui T.Glycation and cardiovascular disease in diabetes:a perspective on the concept of metabolic memory[J].J Diabetes,2017,9(2):141-148.
|
| [18] |
Voronova V,Zhudenkov K,Helmlinger G,et al.Interpretation of metabolic memory phenomenon using a physiological systems model:what drives oxidative stress following glucose normalization[J]?PLoS ONE,2017,12(2):e0171781.
|
| [19] |
Ceriello A,Ihnat MA,Thorpe JE.Clinical review 2:The “metabolic memory”:is more than just tight glucose control necessary to prevent diabetic complications[J]?J Clin Endocrinol Metab,2009,94(2):410-415.
|
| [20] |
Zhao S,Li T,Li J,et al.miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway[J].Diabetologia,2016,59(3):644-654.
|
| [21] |
Infante-Garcia C,Ramos-Rodriguez JJ,Galindo-Gonzalez L,et al.Long-term central pathology and cognitive impairment are exacerbated in a mixed model of Alzheimer′s disease and type 2 diabetes[J].Psychoneuroendocrinology,2016,65:15-25.
|
| [22] |
Chentli F,Azzoug S,Mahgoun S.Diabetes mellitus in elderly[J].Indian J Endocrinol Metab,2015,19(6):744-752.
|
| [23] |
Martins FO,Delgado TC,Viegas J,et al.Mechanisms by which the thiazolidinedione troglitazone protects against sucrose-induced hepatic fat accumulation and hyperinsulinaemia[J].Br J Pharmacol,2016,173(2):267-278.
|
| [24] |
Nathan DM.Diabetes:advances in diagnosis and treatment[J].JAMA,2015,314(10):1052-1062.
|
| [25] |
Yoshida T,Yamagishi S,Nakamura K,et al.Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation[J].Diabetologia,2006,49(12):3094-3099.
|
| [26] |
Katz PM,Leiter LA.The role of the kidney and SGLT2 inhibitors in type 2 diabetes[J].Can J Diabetes,2015,39(Suppl 5):S167-S175.
|
| [27] |
Shimo N,Matsuoka TA,Miyatsuka T,et al.Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions[J].Biochem Biophys Res Commun,2015,467(4):948-954.
|
| [28] |
Dai Y, Dai D, Wang X, et al. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway[J].Cardiovasc Drugs Ther,2014,28(5):425-432.
|
| [29] |
Broxmeyer HE,Pelus LM.Inhibition of DPP4/CD26 and dmPGE2 treatment enhances engraftment of mouse bone marrow hematopoietic stem cells[J].Blood Cells Mol Dis,2014,53(1/2):34-38.
|
| [30] |
Zheng Z,Chen H,Li J,et al.Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin[J].Diabetes,2012,61(1):217-228.
|
| [31] |
Hanefeld M,Monnier L,Schnell O,et al.Early treatment with basal insulin glargine in people with type 2 diabetes: lessons from ORIGIN and other cardiovascular trials[J].Diabetes Ther,2016,7(2):187-201.
|
| [32] |
Ma L,Lu N,Wu G.Antiplatelet aggregation and endothelial protection of I4,a new synthetic anti-diabetes sulfonylurea compound[J].Platelets,2015,26(4):342-348.
|
| [33] |
Hemmingsen B,Lund SS,Gluud C,et al.Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus[J].Cochrane Database Syst Rev,2011(6):CD008143.
|
下载:
